Vanda Pharmaceuticals Inc.
VNDA
$3.92
-$0.06-1.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 201.35M | 198.77M | 190.86M | 182.02M | 177.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.35M | 198.77M | 190.86M | 182.02M | 177.60M |
| Cost of Revenue | 11.40M | 11.31M | 12.18M | 12.70M | 13.46M |
| Gross Profit | 189.96M | 187.46M | 178.67M | 169.33M | 164.14M |
| SG&A Expenses | 166.41M | 146.41M | 130.75M | 117.94M | 106.86M |
| Depreciation & Amortization | 7.01M | 7.27M | 6.47M | 5.10M | 3.73M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 273.80M | 239.43M | 228.33M | 214.49M | 202.80M |
| Operating Income | -72.45M | -40.66M | -37.48M | -32.47M | -25.19M |
| Income Before Tax | -55.63M | -22.92M | -18.09M | -11.96M | -3.85M |
| Income Tax Expenses | -11.38M | -4.02M | -1.70M | -1.03M | 1.04M |
| Earnings from Continuing Operations | -44.25 | -18.90 | -16.39 | -10.93 | -4.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.25M | -18.90M | -16.39M | -10.93M | -4.89M |
| EBIT | -72.45M | -40.66M | -37.48M | -32.47M | -25.19M |
| EBITDA | -64.56M | -32.53M | -30.16M | -26.54M | -20.63M |
| EPS Basic | -0.76 | -0.33 | -0.28 | -0.19 | -0.08 |
| Normalized Basic EPS | -0.67 | -0.32 | -0.29 | -0.22 | -0.14 |
| EPS Diluted | -0.77 | -0.33 | -0.29 | -0.20 | -0.09 |
| Normalized Diluted EPS | -0.67 | -0.32 | -0.29 | -0.22 | -0.14 |
| Average Basic Shares Outstanding | 233.32M | 232.55M | 231.78M | 231.03M | 230.27M |
| Average Diluted Shares Outstanding | 233.32M | 232.55M | 231.78M | 231.11M | 230.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |